A naukri.com initiative
Bioengineer
2d
113
Image Credit: Bioengineer
From Mixed to Matched: New Marker Identifies Therapeutically Relevant Stem Cell–Derived Islets
- Diabetes affects over half a billion people globally, posing significant challenges in healthcare due to pancreatic islet impairment.
- Dr. Eiji Yoshihara and team discovered FXYD2 as a key biomarker for identifying functional stem cell–derived islets suitable for clinical use.
- FXYD2 not only characterizes islet maturity but also plays a role in β cell maturation through ion channel-mediated signaling.
- The study integrated single-cell RNA sequencing to identify dysregulated gene sets, highlighting the mineral absorption pathway regulated by FXYD2.
- FXYD2 expression levels were instrumental in categorizing islet organoids into high and low functional subpopulations.
- Transplantation of FXYD2-high islets in diabetic animal models effectively reversed hyperglycemia, validating the marker's predictive accuracy.
- This breakthrough in identifying FXYD2 enhances the quality control in stem cell–derived islet therapies, making safer and more effective treatments possible.
- The discovery elevates the potential for curing diabetes by enabling precise selection of transplant-ready islets based on FXYD2 expression.
- The research has broader implications, revealing insights into ion channel-mediated signaling and gene regulation, impacting cellular engineering and regenerative medicine.
- Financial support from institutions like the NIH, Breakthrough T1D, and the Allen Foundation emphasized the importance of advancements in stem cell biology for therapeutic interventions.
Read Full Article
6 Likes
For uninterrupted reading, download the app